Gilead Sciences, Inc. (GILD)
151.22
+1.61
(+1.08%)
USD |
NASDAQ |
Sep 03, 16:00
150.80
-0.42
(-0.28%)
Pre-Market: 08:15
Gilead Sciences Research and Development Expense (Annual) : 5.688B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 5.688B |
| December 31, 2024 | 5.816B |
| December 31, 2023 | 5.758B |
| December 31, 2022 | 4.998B |
| December 31, 2021 | 5.363B |
| December 31, 2020 | 4.857B |
| December 31, 2019 | 8.306B |
| December 31, 2018 | 4.198B |
| December 31, 2017 | 3.562B |
| December 31, 2016 | 4.666B |
| December 31, 2015 | 3.014B |
| December 31, 2014 | 2.822B |
| December 31, 2013 | 2.061B |
| December 31, 2012 | 1.690B |
| December 31, 2011 | 1.229B |
| December 31, 2010 | 1.063B |
| December 31, 2009 | 914.22M |
| Date | Value |
|---|---|
| December 31, 2008 | 721.77M |
| December 31, 2007 | 591.03M |
| December 31, 2006 | 383.86M |
| December 31, 2005 | 277.72M |
| December 31, 2004 | 223.55M |
| December 31, 2003 | 164.87M |
| December 31, 2002 | 132.76M |
| December 31, 2001 | 185.55M |
| December 31, 2000 | 131.57M |
| December 31, 1999 | 112.89M |
| December 31, 1998 | 75.30M |
| December 31, 1997 | 59.16M |
| December 31, 1996 | 37.40M |
| December 31, 1995 | 30.01M |
| March 31, 1994 | 23.27M |
| March 31, 1993 | 16.28M |
| March 31, 1992 | 6.200M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.754B |
| AbbVie, Inc. | 8.249B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Amgen, Inc. | 6.974B |
| Biogen, Inc. | 1.481B |